Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer, August 2021

Free Subscription


Abstracts

Retrieve all available abstracts of the following 265 articles:
HTML format


 

Single Articles

  1. GUO L, Wu Q, Ma Z, Yuan M, et al
    Identification of immune-related genes that predict prognosis and risk of bladder cancer: bioinformatics analysis of TCGA database.
    Aging (Albany NY). 2021;13.
    PubMed    
    Abstract available

  2. NGUYEN TP, Zhang CA, Sonn GA, Eisenberg ML, et al
    Consumption of cruciferous vegetables and the risk of bladder cancer in a prospective US cohort: data from the NIH-AARP diet and health study.
    Am J Clin Exp Urol. 2021;9:229-238.
    PubMed    
    Abstract available

  3. LI H, Cao Y, Ma P, Ma Z, et al
    Novel Visualization Methods Assisted Transurethral Resection for Bladder Cancer: An Updated Survival-Based Systematic Review and Meta-Analysis.
    Front Oncol. 2021;11:644341.
    PubMed    
    Abstract available

  4. HE H, Yi L, Zhang B, Yan B, et al
    USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway.
    Int J Biol Sci. 2021;17:2417-2429.
    PubMed    
    Abstract available

  5. ZHENG H, Chen C, Luo Y, Yu M, et al
    Tumor-derived exosomal BCYRN1 activates WNT5A/VEGF-C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer.
    Clin Transl Med. 2021;11:e497.
    PubMed    
    Abstract available

  6. MEI Y, Wu Y, Ma L, Zhang H, et al
    Overexpression of ROCK1 promotes cancer cell proliferation and is associated with poor prognosis in human urothelial bladder cancer.
    Mamm Genome. 2021 Jul 28. pii: 10.1007/s00335-021-09896.
    PubMed    
    Abstract available

  7. HUA S, Xie Z, Wang W, Wan Z, et al
    Identification and Validation of a Novel Immune-Related lncRNA Signature for Bladder Cancer.
    Front Oncol. 2021;11:704946.
    PubMed    
    Abstract available

  8. ZHANG X, Li X, Fu X, Yu M, et al
    Circular RNA TAF4B Promotes Bladder Cancer Progression by Sponging miR-1298-5p and Regulating TGFA Expression.
    Front Oncol. 2021;11:643362.
    PubMed    
    Abstract available

  9. GUPTA A, Gupta S, Siddeek RAT, Chennatt JJ, et al
    Demographic and clinicopathological Profile of Gall Bladder Cancer Patients: Study from a tertiary care center of the Sub-Himalayan region in Indo-Gangetic Belt.
    J Carcinog. 2021;20:6.
    PubMed    
    Abstract available

  10. SEN S, Tuncyurek O, Ertekin E, Dundar M, et al
    The Effect of Spinal and General Anesthesia on Metastatic Lymph Node Flow in Bladder Cancer Surgery: A Pilot Study.
    Agri. 2021;33:142-147.
    PubMed    
    Abstract available

  11. YU X, Liao B, Zhu P, Cheng S, et al
    beta-Caryophyllene induces apoptosis and inhibits cell proliferation by deregulation of STAT-3/mTOR/AKT signaling in human bladder cancer cells: An in vitro study.
    J Biochem Mol Toxicol. 2021 Jul 28:e22863. doi: 10.1002/jbt.22863.
    PubMed    
    Abstract available

  12. LUO Y, Zhou J, Tang J, Zhou F, et al
    MINDY1 promotes bladder cancer progression by stabilizing YAP.
    Cancer Cell Int. 2021;21:395.
    PubMed    
    Abstract available

  13. AMINZADEH Z, Ziamajidi N, Abbasalipourkabir R
    Anticancer Effects of Cinnamaldehyde through Inhibition of ErbB2/HSF1/LDHA Pathway in 5637 Cell Line of Bladder Cancer.
    Anticancer Agents Med Chem. 2021 Jul 26. pii: ACAMC-EPUB-116852.
    PubMed    
    Abstract available

  14. WISNIOWSKI T, Bryda J, Kurzepa J, Watroba S, et al
    The role of matrix metalloproteinases in pathogenesis of human bladder cancer.
    Acta Biochim Pol. 2021 Jul 27. pii: 5600. doi: 10.18388/abp.2020_5600.
    PubMed    
    Abstract available

  15. IIDA K, Miyake M, Murakami K, Komiyama M, et al
    Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy.
    Int J Clin Oncol. 2021 Jul 27. pii: 10.1007/s10147-021-01988.
    PubMed    
    Abstract available

  16. PETZOLD AP, Lubianca FN, Passos LG, Keppler CK, et al
    The impact of preoperative immune checkpoint inhibitors on kidney and bladder cancer surgeries: a systematic review().
    Curr Probl Cancer. 2021 Jul 8:100765. doi: 10.1016/j.currproblcancer.2021.100765
    PubMed    
    Abstract available

  17. HE H, Liu T, Han D, Li C, et al
    Incidence trends and survival prediction of urothelial cancer of the bladder: a population-based study.
    World J Surg Oncol. 2021;19:221.
    PubMed    
    Abstract available

  18. YI E, Yoo YS, Lee S, Park H, et al
    The Experiences of Illness in Korean Bladder Cancer Patients With Radical Cystectomy.
    Cancer Nurs. 2021 Jul 21. pii: 00002820-900000000-98828.
    PubMed    
    Abstract available

  19. YAO Y, Zhang C, Xiong Y, Han B, et al
    [miR-let-7c-5p inhibits invasion and migration of bladder cancer cells by targeting HMGA2].
    Nan Fang Yi Ke Da Xue Xue Bao. 2021;41:1022-1029.
    PubMed    
    Abstract available

  20. ZHI X, Zhou J, Tian H, Zhou R, et al
    [SHOX2 promotes migration, invasion and stemness of bladder cancer cells in vitro].
    Nan Fang Yi Ke Da Xue Xue Bao. 2021;41:995-1001.
    PubMed    
    Abstract available

  21. SINGH B, Kaur P, Gupta S, Guragai N, et al
    Complete Response With Immunotherapy: A Case of Metastatic Bladder Cancer.
    J Investig Med High Impact Case Rep. 2021;9:23247096211035603.
    PubMed    
    Abstract available

  22. YANG C, Wu S, Mou Z, Zhou Q, et al
    Transcriptomic Analysis Identified ARHGAP Family as a Novel Biomarker Associated With Tumor-Promoting Immune Infiltration and Nanomechanical Characteristics in Bladder Cancer.
    Front Cell Dev Biol. 2021;9:657219.
    PubMed    
    Abstract available

  23. JABRA E, Al-Omari A, Haddadin F, Alam W, et al
    Waterpipe Smoking among Bladder Cancer Patients: A Cross-Sectional Study of Lebanese and Jordanian Populations.
    J Smok Cessat. 2021;2021:6615832.
    PubMed    
    Abstract available

  24. GAO D, Niu Q, Gong Y, Guo Q, et al
    Y-Box Binding Protein 1 Regulates Angiogenesis in Bladder Cancer via miR-29b-3p-VEGFA Pathway.
    J Oncol. 2021;2021:9913015.
    PubMed    
    Abstract available

  25. LU H, Mei C, Yang L, Zheng J, et al
    PPM-18, an Analog of Vitamin K, Induces Autophagy and Apoptosis in Bladder Cancer Cells Through ROS and AMPK Signaling Pathways.
    Front Pharmacol. 2021;12:684915.
    PubMed    
    Abstract available

  26. HINSENVELD FJ, Boormans JL, van der Poel HG, van der Schoot DKE, et al
    Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands.
    Urol Oncol. 2021 Jul 21. pii: S1078-1439(21)00277.
    PubMed    
    Abstract available

  27. WIGNER P, Szymanska B, Bijak M, Sawicka E, et al
    Oxidative stress parameters as biomarkers of bladder cancer development and progression.
    Sci Rep. 2021;11:15134.
    PubMed    
    Abstract available

  28. GIL-JULIO H, Perea F, Rodriguez-Nicolas A, Cozar JM, et al
    Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  29. LEE TH, Heo JH, Jeong JY, Lee GH, et al
    Low Expression of EphB2, EphB3, and EphB4 in Bladder Cancer: Novel Potential Indicators of Muscular Invasion.
    Yonsei Med J. 2021;62:679-690.
    PubMed    
    Abstract available

  30. ZOU J, Huang R, Chen Y, Huang X, et al
    Dihydropyrimidinase Like 2 Promotes Bladder Cancer Progression via Pyruvate Kinase M2-Induced Aerobic Glycolysis and Epithelial-Mesenchymal Transition.
    Front Cell Dev Biol. 2021;9:641432.
    PubMed    
    Abstract available

  31. HUMAYUN-ZAKARIA N, Ward DG, Arnold R, Bryan RT, et al
    Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?
    Transl Androl Urol. 2021;10:2787-2808.
    PubMed    
    Abstract available

  32. RUSSELL B, Kotecha P, Thurairaja R, Nair R, et al
    Endoscopic surveillance for bladder cancer: a systematic review of contemporary worldwide practices.
    Transl Androl Urol. 2021;10:2750-2761.
    PubMed    
    Abstract available

  33. NAYAK A, Cresswell J, Mariappan P
    Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer-a systematic review.
    Transl Androl Urol. 2021;10:2737-2749.
    PubMed    
    Abstract available

  34. PAN JW, Zhang X, Jin XW, Wang XJ, et al
    Hydropenia may accelerates the progression of orthotopic bladder cancer induced by N-methyl-N-nitrosourea by increasing the expression levels of AQP1, AQP3, and AQP4.
    Transl Androl Urol. 2021;10:2447-2453.
    PubMed    
    Abstract available

  35. SHADAB R, Nerli RB, Saziya BR, Ghagane SC, et al
    5-ALA-Induced Fluorescent Cytology in the Diagnosis of Bladder Cancer-a Preliminary Report.
    Indian J Surg Oncol. 2021;12:415-420.
    PubMed    
    Abstract available

  36. WANG C, Sun ZQ, Liu MY, Zhang JJ, et al
    [Prognostic analysis of patients with T1 stage high grade of bladder urothelial carcinoma and glandular differentiation].
    Zhonghua Zhong Liu Za Zhi. 2021;43:691-695.
    PubMed    
    Abstract available

  37. GOLKA K, Bothig R, Jungmann O, Forchert M, et al
    [Occupational cancers in urology].
    Urologe A. 2021;60:1061-1072.
    PubMed    
    Abstract available

  38. GOMEZ-MOYANO E, Martinez Garcia S, Hernandez Alcaraz D, Ayala-Blanca M, et al
    Metastatic urothelial carcinoma.
    An Bras Dermatol. 2021;96:519-520.
    PubMed    


  39. PATEL SY, Kubal TE, Li R, Manley BJ, et al
    Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy.
    A A Pract. 2021;15:e01477.
    PubMed    
    Abstract available

  40. YITGIN Y, Erdem S, Serilmez M, Duranyildiz D, et al
    Can serum matrix metalloproteinase-9 and SMAD-2 levels predict lamina propria invasion in bladder urothelial carcinoma?
    Int J Clin Pract. 2021;75:e14277.
    PubMed    
    Abstract available

  41. ALBISINNI S, Martinez Chanza N, Aoun F, Diamand R, et al
    Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era.
    Minerva Urol Nephrol. 2021;73:292-298.
    PubMed    
    Abstract available

  42. MAO X, Chen S, Li G
    Identification of a ten-long noncoding RNA signature for predicting the survival and immune status of patients with bladder urothelial carcinoma based on the GEO database: a superior machine learning model.
    Aging (Albany NY). 2021;13:6957-6981.
    PubMed    
    Abstract available

  43. CHIN S, Song YP
    Double Trouble.
    Int J Radiat Oncol Biol Phys. 2021;109:844-845.
    PubMed    


  44. CHENG S, Zhong W, Xia K, Hong P, et al
    Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study).
    Oncoimmunology. 2021;10:1861737.
    PubMed    
    Abstract available

  45. NAMBIYAR K, Mitra S, Das A, Bal A, et al
    Adenocarcinoma of the colon and urinary bladder: A fortuitous or an embryological phenomenon?
    Indian J Pathol Microbiol. 2021;64:132-135.
    PubMed    
    Abstract available

  46. KARAKAYA YA, Oral E
    Correlation of cyclin D1, HER2, and AMACR expressions with histologic grade in bladder urothelial carcinomas.
    Indian J Pathol Microbiol. 2021;64:84-90.
    PubMed    
    Abstract available

  47. OTTO W, Wieland WF
    [Interactions between radical prostatovesiculectomy and diagnosis of prostate cancer : A medical-historical inventory on the occasion of 20 years of robot-assisted treatment].
    Urologe A. 2021;60:1039-1050.
    PubMed    
    Abstract available

  48. NGUYEN L, Nilforoushan N, Krane JF, Bose S, et al
    Should "suspicious for high-grade urothelial carcinoma" and "positive for high-grade urothelial carcinoma" remain separate categories?
    Cancer Cytopathol. 2021;129:156-163.
    PubMed    
    Abstract available

  49. TIAN W, Shore KT, Shah RB
    Significant reduction of indeterminate (atypical) diagnosis after implementation of The Paris System for Reporting Urinary Cytology: A single-institution study of more than 27,000 cases.
    Cancer Cytopathol. 2021;129:114-120.
    PubMed    
    Abstract available

  50. DINAN MA, Georgieva MV, Li Y, Zhang T, et al
    Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.
    J Geriatr Oncol. 2021;12:298-304.
    PubMed    
    Abstract available

  51. ZHANG ML, Miki Y, Hang JF, Vohra M, et al
    A review of upper urinary tract cytology performance before and after the implementation of The Paris System.
    Cancer Cytopathol. 2021;129:264-274.
    PubMed    
    Abstract available

  52. BABA Y, Kikuchi E, Shigeta K, Ogihara K, et al
    Effects of transurethral resection under general anesthesia on tumor recurrence in non-muscle invasive bladder cancer.
    Int J Clin Oncol. 2021 Aug 6. pii: 10.1007/s10147-021-02000.
    PubMed    
    Abstract available

  53. CHOI JH, Yoo KH, Lee DG, Min GE, et al
    A Case of Incidental Schwannoma Mimicking Necrotic Metastatic Lymph Node from Bladder Cancer.
    Medicina (Kaunas). 2021;57.
    PubMed    
    Abstract available

  54. YANG N, Gao J, Hou R, Xu X, et al
    Grape Seed Proanthocyanidins Inhibit Migration and Invasion of Bladder Cancer Cells by Reversing EMT through Suppression of TGF-beta Signaling Pathway.
    Oxid Med Cell Longev. 2021;2021:5564312.
    PubMed    
    Abstract available

  55. XIONG H, Gao H, Hu J, Dai Y, et al
    Prognostic Implications of Immune-Related Gene Pairs Signatures in Bladder Cancer.
    J Oncol. 2021;2021:5345181.
    PubMed    
    Abstract available

  56. DELLIS A, Zakopoulou R, Kougioumtzopoulou A, Tzannis K, et al
    Referral for "Neoadjuvant Chemotherapy" for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes.
    Cancer Manag Res. 2021;13:5941-5955.
    PubMed    
    Abstract available

  57. GALESLOOT TE, Grotenhuis AJ, Kolev D, Aben KK, et al
    Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2021 Aug 2. pii: S2588-9311(21)00120.
    PubMed    
    Abstract available

  58. HORIBE Y, Ujike T, Fukuhara S, Fujita K, et al
    [A Case of Para-Aortic Lymph Node Metastasis 10 Years after Transurethral Resection for Non-Muscle Invasive Bladder Cancer].
    Hinyokika Kiyo. 2021;67:327-330.
    PubMed    
    Abstract available

  59. EZEABIKWA B, Mondal N, Antonopoulos A, Haslam SM, et al
    Major differences in glycosylation and Fucosyltransferase expression in low-grade versus high-grade bladder cancer cell lines.
    Glycobiology. 2021 Aug 5. pii: 6338188. doi: 10.1093.
    PubMed    
    Abstract available

  60. CHENG F, Zheng B, Si S, Wang J, et al
    The Roles of CircRNAs in Bladder Cancer: Biomarkers, Tumorigenesis Drivers, and Therapeutic Targets.
    Front Cell Dev Biol. 2021;9:666863.
    PubMed    
    Abstract available

  61. FAN B, Mohammed A, Huang Y, Luo H, et al
    Can Aspirin Use Be Associated With the Risk or Prognosis of Bladder Cancer? A Case-Control Study and Meta-analytic Assessment.
    Front Oncol. 2021;11:633462.
    PubMed    
    Abstract available

  62. LI Z, Li Y, Zhong W, Huang P, et al
    m6A-Related lncRNA to Develop Prognostic Signature and Predict the Immune Landscape in Bladder Cancer.
    J Oncol. 2021;2021:7488188.
    PubMed    
    Abstract available

  63. BAUMANN BC, Sargos P, Efstathiou JA
    Standard Versus Hypofractionated Radiation Therapy for Bladder Cancer: New Insights, but Questions Remain.
    Int J Radiat Oncol Biol Phys. 2021;111:113-116.
    PubMed    


  64. ARIAFAR A, Zareinejad M, Soltani M, Vahidi Y, et al
    GM-CSF-producing lymphocytes in tumor-draining lymph nodes of patients with bladder cancer.
    Eur Cytokine Netw. 2021;32:1-7.
    PubMed    
    Abstract available

  65. ULERI A, Hurle R, Contieri R, Diana P, et al
    Combination of AST to ALT and neutrophils to lymphocytes ratios as predictors of locally advanced disease in patients with bladder cancer subjected to radical cystectomy: Results from a single-institutional series.
    Urologia. 2021 Aug 4:3915603211035191. doi: 10.1177/03915603211035191.
    PubMed    
    Abstract available

  66. DONG M, Nie A, Liu C, Zheng J, et al
    Psychological resilience of patients with bladder cancer after radical cystectomy and urinary diversion: a cross-sectional study.
    Psychooncology. 2021 Aug 3. doi: 10.1002/pon.5770.
    PubMed    
    Abstract available

  67. YANG Z, Sun H, Ma W, Wu K, et al
    Down-regulation of Polo-like kinase 4 (PLK4) induces G1 arrest via activation of the p38/p53/p21 signalling pathway in bladder cancer.
    FEBS Open Bio. 2021 Aug 3. doi: 10.1002/2211-5463.13262.
    PubMed    
    Abstract available

  68. DE QUEIROZ NMGP, Marinho FV, de Araujo ACVSC, Fahel JS, et al
    MyD88-dependent BCG immunotherapy reduces tumor and regulates tumor microenvironment in bladder cancer murine model.
    Sci Rep. 2021;11:15648.
    PubMed    
    Abstract available

  69. ZHOU R, Liang J, Chen Q, Tian H, et al
    Development and validation of an intra-tumor heterogeneity-related signature to predict prognosis of bladder cancer: a study based on single-cell RNA-seq.
    Aging (Albany NY). 2021;13.
    PubMed    
    Abstract available

  70. PACIOTTI M, Contieri R, Fasulo V, Casale P, et al
    Active surveillance for recurrent Non-Muscle Invasive Bladder Cancer (NMIBC): which lessons have we learned during COVID-19 pandemia?
    Minerva Urol Nephrol. 2021 Aug 2. pii: S2724-6051.21.04613.
    PubMed    


  71. KAFKASLI A, Yazici O, Can U, Dincer E, et al
    Testosterone status is not associated with bladder cancer parameters in adult male patients: results of a prospective controlled study.
    Aging Male. 2021;24:101-105.
    PubMed    
    Abstract available

  72. XUE C, Chen X, Lin K, Tong Y, et al
    Identification of Notch signaling pathway gene mutations as a prognostic biomarker for bladder cancer.
    Future Oncol. 2021 Aug 2. doi: 10.2217/fon-2021-0110.
    PubMed    
    Abstract available

  73. KUMAR A, Cherry DR, Courtney PT, Nalawade V, et al
    Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans.
    Eur Urol Open Sci. 2021;30:1-10.
    PubMed    
    Abstract available

  74. CHENARD S, Jackson C, Vidotto T, Chen L, et al
    Sexual Dimorphism in Outcomes of Non-muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint.
    Eur Urol Open Sci. 2021;29:50-58.
    PubMed    
    Abstract available

  75. FROEHNER M, Koch R, Heberling U, Borkowetz A, et al
    Decreasing Non-bladder-cancer Mortality After Radical Cystectomy.
    Eur Urol Open Sci. 2021;29:15-18.
    PubMed    
    Abstract available

  76. MAIBOM SL, Roder MA, Poulsen AM, Thind PO, et al
    Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer.
    Eur Urol Open Sci. 2021;28:1-8.
    PubMed    
    Abstract available

  77. WEISS S, Hallmann S, Koch S, Eidt S, et al
    Identifying the Molecular Mechanisms Contributing to Progression, Metastasis, and Death in Low-grade Non-muscle-invasive Bladder Cancer: A Case Report.
    Eur Urol Open Sci. 2021;27:29-32.
    PubMed    
    Abstract available

  78. MUTO S, Lu Y, Ide H, Yamaguchi R, et al
    The Use of Urine Mycobacterium tuberculosis Complex Polymerase Chain Reaction as a Predictive Factor for Recurrence and Progression After Intravesical Bacillus Calmette-Guerin Therapy in Patients with Non-muscleinvasive Bladder Cancer.
    Eur Urol Open Sci. 2021;27:10-18.
    PubMed    
    Abstract available

  79. PACIOTTI M, Casale P, Colombo P, Fasulo V, et al
    Long-term Follow-up After En Bloc Transurethral Resection of Non-muscle-invasive Bladder Cancer: Results from a Single-center Experience.
    Eur Urol Open Sci. 2021;26:64-71.
    PubMed    
    Abstract available

  80. REZAEE ME, Ismail AAO, Okorie CL, Seigne JD, et al
    Partial Versus Complete Bacillus Calmette-Guerin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non-muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
    Eur Urol Open Sci. 2021;26:35-43.
    PubMed    
    Abstract available

  81. REESINK DJ, van de Garde EMW, Somford DM, Meijer RP, et al
    Development of the First Patient-centred Set of Outcomes for Muscle-invasive and Metastatic Bladder Cancer: A Multicentre Initiative.
    Eur Urol Open Sci. 2021;26:18-26.
    PubMed    
    Abstract available

  82. XU X, Wang H, Guo Y, Zhang X, et al
    Study Progress of Noninvasive Imaging and Radiomics for Decoding the Phenotypes and Recurrence Risk of Bladder Cancer.
    Front Oncol. 2021;11:704039.
    PubMed    
    Abstract available

  83. XIE Y, Zhu S, Zang J, Wu G, et al
    ADNP prompts the cisplatin-resistance of bladder cancer via TGF-beta-mediated epithelial-mesenchymal transition (EMT) pathway.
    J Cancer. 2021;12:5114-5124.
    PubMed    
    Abstract available

  84. ZHANG Y, Chen L, Luo G
    Long non-coding RNA PCAT6 regulates bladder cancer progression via the microRNA-143-3p/PDIA6 axis.
    Exp Ther Med. 2021;22:947.
    PubMed    
    Abstract available

  85. NASPRO R, La Croce G, Finati M, Roscigno M, et al
    Oncological outcomes of concomitant carcinoma in situ at radical cystectomy in pure urothelial bladder cancer and in histological variants.
    Urol Oncol. 2021 Jul 29. pii: S1078-1439(21)00310.
    PubMed    
    Abstract available

  86. HO P, Moran GW, Wang V, Li G, et al
    The effect of tumor grade heterogeneity on recurrence in non-muscle invasive bladder cancer.
    Urol Oncol. 2021 Jul 29. pii: S1078-1439(21)00304.
    PubMed    
    Abstract available

  87. QIAN Z, Ding W, Zhou Q, Ge S, et al
    Increased Risk of Recurrence of Non-Muscle Invasive Bladder Cancer Associated with Psychological Distress: A Prospective Cohort Study.
    Psychiatry Investig. 2021 Aug 2. pii: pi.2021.0022. doi: 10.30773/pi.2021.0022.
    PubMed    
    Abstract available

  88. FEUER Z, Matulewicz RS, Bjurlin MA
    Letter to the editor Re: Shore ND, Palou Redorta J, Robert G, et al. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. Urol oncol. Published online june 21, 2021:S1078-1439(21)00221-0.
    Urol Oncol. 2021 Jul 28. pii: S1078-1439(21)00313.
    PubMed    


  89. KUFUKIHARA R, Kikuchi E, Shigeta K, Ogihara K, et al
    Diagnostic performance of the vesical imaging-reporting and data system for detecting muscle-invasive bladder cancer in real clinical settings: Comparison with diagnostic cystoscopy.
    Urol Oncol. 2021 Jul 28. pii: S1078-1439(21)00306.
    PubMed    
    Abstract available

  90. SONMEZ G, Tolga Tombul S, Herdem N, Demirtas T, et al
    Superselective vesical artery embolization versus intravesical formalin for intractable hematuria in patients with bladder cancer.
    Actas Urol Esp. 2021 Jul 28. pii: S0210-4806(21)00121.
    PubMed    
    Abstract available

  91. DAI R, Jiang Q, Zhou Y, Lin R, et al
    Lnc-STYK1-2 regulates bladder cancer cell proliferation, migration, and invasion by targeting miR-146b-5p expression and AKT/STAT3/NF-kB signaling.
    Cancer Cell Int. 2021;21:408.
    PubMed    
    Abstract available

  92. ZHANG N, Hua X, Tu H, Li J, et al
    Isorhapontigenin (ISO) inhibits EMT through FOXO3A/METTL14/VIMENTIN pathway in bladder cancer cells.
    Cancer Lett. 2021 Jul 28. pii: S0304-3835(21)00374.
    PubMed    
    Abstract available

  93. ROMER E, Esperto F, Dooldeniya M, Cumberbatch MG, et al
    Does minimally invasive surgery for bladder cancer result in unusual sites of metastasis?
    Actas Urol Esp (Engl Ed). 2021 Jul 27. pii: S2173-5786(21)00077.
    PubMed    
    Abstract available

  94. SIKIC D, Eckstein M, Weyerer V, Kubon J, et al
    High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer.
    Urol Oncol. 2021 Jul 27. pii: S1078-1439(21)00297.
    PubMed    
    Abstract available

  95. PINTO A, Alvarez-Maestro M
    Adjuvant immunotherapy in muscle-invasive bladder cancer: Closer than it seems?
    Actas Urol Esp. 2021 Jul 27. pii: S0210-4806(21)00102.
    PubMed    


  96. LI C, Han D, Huang Q, Xu F, et al
    Competing-risks nomogram for predicting cancer-specific death in upper tract urothelial carcinoma: a population-based analysis.
    BMJ Open. 2021;11:e048243.
    PubMed    
    Abstract available

  97. KHALIFA J, Supiot S, Pignot G, Hennequin C, et al
    Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder.
    Radiother Oncol. 2021;161:95-114.
    PubMed    
    Abstract available

  98. DO CARMO SILVA J, Babjuk M, Vesely S, Dusek P, et al
    Morbidity and mortality after open radical cystectomy and ileal diversion - 10 years experience and a comprehensive assessment in a single tertiary center.
    Neoplasma. 2021;68:882-891.
    PubMed    
    Abstract available

  99. BOGDAN G
    Editorial Comment on: "Primary Complete Transurethral Resection of Bladder Tumor Using Photodynamic Diagnosis for High-Risk Nonmuscle Invasive Bladder Cancer: Is a Restaging Photodynamic Transurethral Resection Really Necessary?" by Tadrist et al.
    J Endourol. 2021;35:1047-1048.
    PubMed    


  100. GUO L, Wang X, Wang S, Hua L, et al
    Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
    Oncoimmunology. 2021;10:1887551.
    PubMed    
    Abstract available

  101. AL-OBAIDY KI, Cheng L
    Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder.
    J Clin Pathol. 2021;74:491-495.
    PubMed    
    Abstract available

  102. DE LORENZIS E, Albo G, Longo F, Bebi C, et al
    Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma.
    Genes (Basel). 2021;12.
    PubMed    
    Abstract available

  103. KODAMA H, Yoneyama T, Tanaka T, Noro D, et al
    N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas.
    Cancer Med. 2021;10:1297-1313.
    PubMed    
    Abstract available

  104. PINI GM, Uccella S, Corinti M, Colecchia M, et al
    Primary MiNEN of the urinary bladder: an hitherto undescribed entity composed of large cell neuroendocrine carcinoma and adenocarcinoma with a distinct clinical behavior : Description of a case and review of the pertinent literature.
    Virchows Arch. 2021;479:69-78.
    PubMed    
    Abstract available

  105. VARGAS AC, Burchett I, Turner J, Delprado W, et al
    Monotypic Plasma Cell Proliferation of Uncertain Clinical Significance Mimicking Interstitial Cystitis: An Early Lesion of MALT Lymphoma?
    Am J Surg Pathol. 2021;Publish Ahead of Print.
    PubMed    
    Abstract available

  106. MERDER E, Can O, Ariman A, Polat EC, et al
    Our laparoscopic cystectomy experiences.
    Urologia. 2021;88:30-33.
    PubMed    
    Abstract available

  107. BEJI S, Wrist Lam G, Ostergren PB, Toxvaerd A, et al
    Diagnostic value of probe-based confocal laser endomicroscopy versus conventional endoscopic biopsies of non-muscle invasive bladder tumors: a pilot study.
    Scand J Urol. 2021;55:36-40.
    PubMed    
    Abstract available

  108. CHIANCONE F, Fabiano M, Califano A, Langella NA, et al
    Massive intra-abdominal recurrence after robotic-assisted radical cystectomy: A case report and critical appraisal of literature.
    Urologia. 2021;88:21-24.
    PubMed    
    Abstract available

  109. ESPANA-NAVARRO R, Rabadan-Marquez P, Perez-Arguelles D, Sanchez-Martinez N, et al
    Implementation of ERAS (Enhanced Recovery After Surgery) protocols for radical cystectomy patients: The pathway to standardization. A systematic review.
    Actas Urol Esp (Engl Ed). 2021;45:103-115.
    PubMed    
    Abstract available

  110. WANG Y, Zhang Z, Shao J, Lu Y, et al
    Outcome of simultaneous thulium laser enucleation of bladder tumor and prostate in patients with non-muscle invasive bladder tumor and benign prostatic hyperplasia: a matched-pair comparison with a long-term follow-up.
    World J Urol. 2021;39:105-111.
    PubMed    
    Abstract available

  111. GOUIN KH 3RD, Ing N, Plummer JT, Rosser CJ, et al
    An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer.
    Nat Commun. 2021;12:4906.
    PubMed    
    Abstract available

  112. XIAO S, Chen Y, Luan T, Huang Y, et al
    MicroRNA-20a Targeting LASS2 Promotes the Proliferation, Invasiveness and Migration of Bladder Cancer.
    Clin Lab. 2021;67.
    PubMed    
    Abstract available

  113. XU X, Zhu Y, Ye S, Li S, et al
    Association of Dietary Carrot Intake With Bladder Cancer Risk in a Prospective Cohort of 99,650 Individuals With 12.5 Years of Follow-Up.
    Front Nutr. 2021;8:669630.
    PubMed    
    Abstract available

  114. FERREIRA JM, Matheus LHG, de Almeida RVS, Melo PAS, et al
    High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer.
    Oncotarget. 2021;12:1580-1586.
    PubMed    
    Abstract available

  115. SHARMA G
    Comment on "Pooled analysis of Xpert bladder cancer based on the 5 mRNAs for rapid diagnosis of bladder carcinoma".
    World J Surg Oncol. 2021;19:237.
    PubMed    
    Abstract available

  116. KOBAYASHI M, Fujiyama N, Tanegashima T, Narita S, et al
    Effect of HLA genotype on intravesical recurrence after bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer.
    Cancer Immunol Immunother. 2021 Aug 11. pii: 10.1007/s00262-021-03032.
    PubMed    
    Abstract available

  117. TAYLOR CA, Tobert CM, Kahnoski RJ, Humphrey JE, et al
    The value of a comprehensive primary outcome - results of a negative randomized control trial in the non-muscle invasive bladder cancer population.
    Can J Urol. 2021;28:10756-10761.
    PubMed    
    Abstract available

  118. AMAYA-FRAGOSO E, Dantes-Duran MA, Perez-Torres EK, Garcia-Perez CM, et al
    [Osteoclast-Like giant cell bladder carcinoma: Case report].
    Rev Med Inst Mex Seguro Soc. 2021;59:253-259.
    PubMed    
    Abstract available

  119. LAI C, Wu Z, Li Z, Yu H, et al
    A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.
    Cancer Med. 2021 Aug 10. doi: 10.1002/cam4.4167.
    PubMed    
    Abstract available

  120. D'ANDREA D, Black PC, Zargar H, Zargar-Shoshtari K, et al
    Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer.
    World J Urol. 2021 Aug 9. pii: 10.1007/s00345-021-03793.
    PubMed    
    Abstract available

  121. ABDO N, Alsoukhni M, Batieha A, Arqoub K, et al
    Survival of patients with urinary bladder cancer in Jordan, 2005-2014.
    East Mediterr Health J. 2021;27:648-655.
    PubMed    
    Abstract available

  122. DONG B, Liang J, Li D, Song W, et al
    Identification of a Prognostic Signature Associated With the Homeobox Gene Family for Bladder Cancer.
    Front Mol Biosci. 2021;8:688298.
    PubMed    
    Abstract available

  123. LUO C, Huang B, Wu Y, Xu Y, et al
    Identification of Lymph Node Metastasis-Related Key Genes and Prognostic Risk Model in Bladder Cancer by Co-Expression Analysis.
    Front Mol Biosci. 2021;8:633299.
    PubMed    
    Abstract available

  124. IKEDA T, Hasegawa G, Kawaguchi G, Ikeda Y, et al
    Successful Response of Pembrolizumab Rechallenge after Radiotherapy for a Patient with Bladder Cancer of Nonresponse of Pembrolizumab First Challenge.
    Case Rep Urol. 2021;2021:9087529.
    PubMed    
    Abstract available

  125. ZHU J, Huang Y, Zhang Y, Huang R, et al
    KCNMB2-AS1 Promotes Bladder Cancer Progression Through Sponging miR-374a-3p to Upregulate S100A10.
    Front Genet. 2021;12:655569.
    PubMed    
    Abstract available

  126. ZHANG Q, Liu Y, Chen P, Shi X, et al
    Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer.
    Bioengineered. 2021;12:4946-4961.
    PubMed    
    Abstract available

  127. ZHANG Z, Mou Z, Xu C, Wu S, et al
    Autophagy-associated circular RNA hsa_circ_0007813 modulates human bladder cancer progression via hsa-miR-361-3p/IGF2R regulation.
    Cell Death Dis. 2021;12:778.
    PubMed    
    Abstract available

  128. BELUGINA R, Karpushchenko E, Sleptsov A, Protoshchak V, et al
    Developing non-invasive bladder cancer screening methodology through potentiometric multisensor urine analysis.
    Talanta. 2021;234:122696.
    PubMed    
    Abstract available

  129. DE LIMA FRAGELLI BD, Camillo L, de Almeida Rodolpho JM, de Godoy KF, et al
    Antitumor Effect of IL-2 and TRAIL Proteins Expressed by Recombinant Salmonella in Murine Bladder Cancer Cells.
    Cell Physiol Biochem. 2021;55:460-476.
    PubMed    
    Abstract available

  130. WIGNER P, Bijak M, Saluk-Bijak J
    The Green Anti-Cancer Weapon. The Role of Natural Compounds in Bladder Cancer Treatment.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  131. ECKSTEIN M, Lieb V, Jung R, Sikic D, et al
    Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients.
    Cells. 2021;10.
    PubMed    
    Abstract available

  132. HEPBURN AC, Lazzarini N, Veeratterapillay R, Wilson L, et al
    Identification of CNGB1 as a Predictor of Response to Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  133. ZHENG X, Wezel F, Azoitei A, Meessen S, et al
    Shorter Leukocyte Telomere Length Is Associated with Worse Survival of Patients with Bladder Cancer and Renal Cell Carcinoma.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  134. ISHIBASHI Y, Yamaguchi K, Hayashi Y, Onuki T, et al
    [Clear Cell Variant of Invasive Urothelial Carcinoma of the Renal Pelvis: A Case Report].
    Hinyokika Kiyo. 2021;67:313-316.
    PubMed    
    Abstract available

  135. SUGINO Y, Nishikawa K, Kato M, Sasaki T, et al
    [Initial Experience of Photodynamic Diagnosis-Assisted Transurethral Resection of Bladder Tumor (PDD-TURBT)].
    Hinyokika Kiyo. 2021;67:303-308.
    PubMed    
    Abstract available

  136. BRAZAO ES JUNIOR, Coser DG, Meduna RR, da Costa WH, et al
    Simultaneous laparoscopic nephroureterectomy and robot-assisted anterior pelvic exenteration with intracorporeal ileal conduit urinary diversion: step-by-step video-illustrated technique.
    Int Braz J Urol. 2021;47:1072-1073.
    PubMed    
    Abstract available

  137. ANAISSIE J, Dursun F, Wallis CJD, Klaassen Z, et al
    Dissecting the role of radical cystectomy and urinary diversion in post-operative complications: an analysis using the American College of Surgeons national surgical quality improvement program database.
    Int Braz J Urol. 2021;47:1006-1019.
    PubMed    
    Abstract available

  138. ROUF BANDAY A, Onabajo OO, Lin SH, Obajemu A, et al
    Targeting natural splicing plasticity of APOBEC3B restricts its expression and mutagenic activity.
    Commun Biol. 2021;4:386.
    PubMed    
    Abstract available

  139. CAO J, Li J, Yang X, Li P, et al
    Transcriptomics analysis for the identification of potential age-related genes and cells associated with three major urogenital cancers.
    Sci Rep. 2021;11:641.
    PubMed    
    Abstract available

  140. DEUKER M, Stolzenbach LF, Colla Ruvolo C, Nocera L, et al
    Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma.
    Clin Genitourin Cancer. 2021;19:117-124.
    PubMed    
    Abstract available

  141. DO OA, Ferris LA, Holt SK, Ramos JD, et al
    Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens.
    Clin Genitourin Cancer. 2021;19:125-134.
    PubMed    
    Abstract available

  142. SFAKIANOS JP, Salome B, Daza J, Farkas A, et al
    Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer.
    Urol Oncol. 2021;39:121-129.
    PubMed    
    Abstract available

  143. BHANVADIA RR, Khouri RK Jr, Ashbrook C, Woldu SL, et al
    Safety, Efficacy, and Impact on Quality of Life of Palliative Robotic Cystectomy for Advanced Prostate Cancer.
    Clin Genitourin Cancer. 2021;19:e129-e134.
    PubMed    


  144. RAZDAN S, Sljivich M, Pfail J, Wiklund PK, et al
    Predicting morbidity and mortality after radical cystectomy using risk calculators: A comprehensive review of the literature.
    Urol Oncol. 2021;39:109-120.
    PubMed    
    Abstract available

  145. MORALES A, Siemens DR, Koti M
    At a time of global BCG shortage, attempts at optimizing BCG dose and schedule is no longer the answer.
    Urol Oncol. 2021;39:137-138.
    PubMed    


  146. HIRD AE, Magee DE, Cheung DC, Sander B, et al
    Neoadjuvant Versus Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Microsimulation Model.
    Clin Genitourin Cancer. 2021;19:e135-e147.
    PubMed    
    Abstract available

  147. DIAMANTOPOULOS LN, Holt SK, Khaki AR, Sekar RR, et al
    Response to Neoadjuvant Chemotherapy and Survival in Micropapillary Urothelial Carcinoma: Data From a Tertiary Referral Center and the Surveillance, Epidemiology, and End Results (SEER) Program.
    Clin Genitourin Cancer. 2021;19:144-154.
    PubMed    
    Abstract available

  148. PIERCONTI F, Martini M, Fiorentino V, Cenci T, et al
    The combination cytology/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?
    Urol Oncol. 2021;39:131.
    PubMed    
    Abstract available

  149. QUHAL F, D'Andrea D, Soria F, Moschini M, et al
    Primary Ta high grade bladder tumors: Determination of the risk of progression.
    Urol Oncol. 2021;39:132.
    PubMed    
    Abstract available

  150. AMIR M, Qureshi MA, Javed S
    Biomolecular interactions and binding dynamics of tyrosine kinase inhibitor erdafitinib, with human serum albumin.
    J Biomol Struct Dyn. 2021;39:3934-3947.
    PubMed    
    Abstract available

  151. ROSIELLO G, Pecoraro A, Palumbo C, Knipper S, et al
    Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study.
    World J Urol. 2021;39:813-822.
    PubMed    
    Abstract available

  152. MAZZONE E, D'Hondt F, Beato S, Andras I, et al
    Robot-assisted radical cystectomy with intracorporeal urinary diversion decreases postoperative complications only in highly comorbid patients: findings that rely on a standardized methodology recommended by the European Association of Urology Guideli
    World J Urol. 2021;39:803-812.
    PubMed    
    Abstract available

  153. ZHONG W, Wang D, Yao B, Chen X, et al
    Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer.
    J Zhejiang Univ Sci B. 2021;22:664-681.
    PubMed    
    Abstract available

  154. ARNOLD CR, Lindner AK, Schachtner G, Tulchiner G, et al
    Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer-a valid option for cisplatin-unfit patients?
    Strahlenther Onkol. 2021 Aug 19. pii: 10.1007/s00066-021-01837.
    PubMed    
    Abstract available

  155. LIAO CH, Tsai CW, Chang WS, Wang ZH, et al
    Association of Matrix Metalloproteinase-1 Genotypes With Bladder Cancer Risk.
    In Vivo. 2021;35:2535-2540.
    PubMed    
    Abstract available

  156. WELK B
    The argument against screening for bladder cancer in neuro-urological patients.
    World J Urol. 2021 Aug 19. pii: 10.1007/s00345-021-03802.
    PubMed    
    Abstract available

  157. PENG M, Cheng X, Xiong W, Yi L, et al
    Integrated Analysis of a Competing Endogenous RNA Network Reveals a Prognostic lncRNA Signature in Bladder Cancer.
    Front Oncol. 2021;11:684242.
    PubMed    
    Abstract available

  158. KATO Y, Ikarashi D, Kikuchi D, Takayama M, et al
    Dysuria therapeutic agents as an independent prognostic factor for the primary recurrence of non-muscle invasive bladder cancer: a propensity score matching study.
    J Int Med Res. 2021;49:3000605211037478.
    PubMed    
    Abstract available

  159. WANG W, Zhang M, Huang Z, Wang L, et al
    Knockdown of CXCL5 inhibits the invasion, metastasis and stemness of bladder cancer lung metastatic cells by downregulating CD44.
    Anticancer Drugs. 2021 Aug 16. pii: 00001813-900000000-98308.
    PubMed    
    Abstract available

  160. MIYATA H, Hirohashi Y, Yamada S, Yanagawa J, et al
    GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
    Cancer Immunol Immunother. 2021 Aug 18. pii: 10.1007/s00262-021-03025.
    PubMed    
    Abstract available

  161. LIAO Y, Zou X, Wang K, Wang Y, et al
    Comprehensive analysis of Transcription Factors identified novel prognostic biomarker in human bladder cancer.
    J Cancer. 2021;12:5605-5621.
    PubMed    
    Abstract available

  162. CHEN H, Pan Y, Jin X, Chen G, et al
    An immune cell infiltration-related gene signature predicts prognosis for bladder cancer.
    Sci Rep. 2021;11:16679.
    PubMed    
    Abstract available

  163. FLOR JMS, Gaston MJFV, Lapitan MCM
    Pelvic lipomatosis associated with bilateral obstructive uropathy and proliferative cystitis.
    BMJ Case Rep. 2021;14.
    PubMed    
    Abstract available

  164. HUANG R, Zheng Z, Xian S, Zhang J, et al
    Identification of prognostic and bone metastatic alternative splicing signatures in bladder cancer.
    Bioengineered. 2021;12:5289-5304.
    PubMed    
    Abstract available

  165. PARK YM, Seo HI, Hong SB, Kim S, et al
    Curative resection of bladder cancer with pancreas head metastasis.
    Ann Hepatobiliary Pancreat Surg. 2021;25:440-444.
    PubMed    
    Abstract available

  166. YEH J, Bressel M, Tai KH, Kron T, et al
    A retrospective review of the long-term outcomes of online adaptive radiation therapy and conventional radiation therapy for muscle invasive bladder cancer.
    Clin Transl Radiat Oncol. 2021;30:65-70.
    PubMed    
    Abstract available

  167. YUAN JB, Gu L, Chen L, Yin Y, et al
    Annexin A8 regulated by lncRNA-TUG1/miR-140-3p axis promotes bladder cancer progression and metastasis.
    Mol Ther Oncolytics. 2021;22:36-51.
    PubMed    
    Abstract available

  168. MIYAKE M, Nishimura N, Oda Y, Owari T, et al
    Intravesical Bacillus Calmette-Guerin treatment-induced sleep quality deterioration in patients with non-muscle invasive bladder cancer: functional outcome assessment based on a questionnaire survey and actigraphy.
    Support Care Cancer. 2021 Aug 16. pii: 10.1007/s00520-021-06468.
    PubMed    
    Abstract available

  169. GUO W, Gai Q, Ma Y, Shan Z, et al
    LINC01410 leads the migration, invasion and EMT of bladder cancer cells by modulating miR-4319 / Snail1.
    Cancer Cell Int. 2021;21:429.
    PubMed    
    Abstract available

  170. HUANG ZM, Wang H, Ji ZG
    Bladder mesenchymal stromal cell-derived exosomal miRNA-217 modulates bladder cancer cell survival through Hippo-YAP pathway.
    Inflamm Res. 2021 Aug 14. pii: 10.1007/s00011-021-01494.
    PubMed    
    Abstract available

  171. FERNANDEZ AVILA C, Garcia-Baquero Garcia de Paredes R, Aguera Bitaube J, Caro Romero A, et al
    Extensive keratinising squamous metaplasia of bladder.
    Arch Esp Urol. 2021;74:635-636.
    PubMed    


  172. ZEUSCHNER P, Linxweiler J, Mohr R, van Heemskerk S, et al
    Robot-assisted versus open radical cystectomy: A cohort study on perioperative outcomes accounting for stage selection bias and surgical experience.
    Int J Med Robot. 2021;17:e2258.
    PubMed    
    Abstract available

  173. ABEL M, Burkenroad A, Sun A, Lu E, et al
    The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.
    Clin Genitourin Cancer. 2021;19:183-193.
    PubMed    
    Abstract available

  174. LANGE K, Gorvet M, Raman S
    Laparoscopic right colectomy following an ileal orthotopic neobladder - a video vignette.
    Colorectal Dis. 2021;23:754-755.
    PubMed    


  175. AZIZ A, Raza SJ, Davaro F, May A, et al
    Stage Migration for Upper Tract Urothelial Cell Carcinoma.
    Clin Genitourin Cancer. 2021;19:e184-e192.
    PubMed    
    Abstract available

  176. NELSON L, Alanee S, Ali A
    Robotic-assisted creation of a sigmoid neobladder following cystectomy - a video vignette.
    Colorectal Dis. 2021;23:329-330.
    PubMed    


  177. FOERSTER B, Abufaraj M, Mari A, Seisen T, et al
    The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC).
    Clin Genitourin Cancer. 2021;19:272.
    PubMed    
    Abstract available

  178. DU Y, Yang R, Chen Z, Wang L, et al
    A deep learning network-assisted bladder tumour recognition under cystoscopy based on Caffe deep learning framework and EasyDL platform.
    Int J Med Robot. 2021;17:1-8.
    PubMed    
    Abstract available

  179. HALFORD Z, Anderson MK, Clark MD
    Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Ann Pharmacother. 2021;55:772-782.
    PubMed    
    Abstract available

  180. HALE O, Patterson K, Lai Y, Meng Y, et al
    Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
    Clin Genitourin Cancer. 2021;19:e17-e30.
    PubMed    
    Abstract available

  181. LOPEZ RAMIREZ C, Gomez Izquierdo L, Rodriguez Portal JA
    Granulomatous lung disease associated with the use of intravesical mytomycin.
    Med Clin (Barc). 2021;157:206-207.
    PubMed    


  182. SUAREZ-IBARROLA R, Braun L, Pohlmann PF, Becker W, et al
    Metabolic Imaging of Urothelial Carcinoma by Simultaneous Autofluorescence Lifetime Imaging (FLIM) of NAD(P)H and FAD.
    Clin Genitourin Cancer. 2021;19:e31-e36.
    PubMed    


  183. KAGAN J, Alemozaffar M, Carthon B, Osunkoya AO, et al
    Surgical Pathology Findings in Patients Who Have Undergone Radical Cystectomy/Cystoprostatectomy With Extended Versus Standard Lymph Node Dissection for Urothelial Carcinoma of the Bladder: A Contemporary Analysis.
    Int J Surg Pathol. 2021;29:150-154.
    PubMed    
    Abstract available

  184. RAMMANT E, Van Hecke A, Decaestecker K, Albersen M, et al
    Supportive care needs and utilization of bladder cancer patients undergoing radical cystectomy: A longitudinal study.
    Psychooncology. 2021 Aug 27. doi: 10.1002/pon.5795.
    PubMed    
    Abstract available

  185. NIKULAINEN I, Salminen AP, Jambor I, Merisaari H, et al
    Visual MRI T-category versus VI-RADS evaluation from multiparametric MRI in the detection of muscle-invasion in patients with suspected bladder cancer: single centre registered clinical trial (MIB-trial).
    Scand J Urol. 2021 Aug 27:1-7. doi: 10.1080/21681805.2021.1971290.
    PubMed    
    Abstract available

  186. SIKIC D, Taubert H, Breyer J, Eckstein M, et al
    The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer.
    Cancer Manag Res. 2021;13:6567-6578.
    PubMed    
    Abstract available

  187. KIM JH, Lee S, Kang SJ, Choi YW, et al
    Establishment of Three-Dimensional Bioprinted Bladder Cancer-on-a-Chip with a Microfluidic System Using Bacillus Calmette-Guerin.
    Int J Mol Sci. 2021;22.
    PubMed    
    Abstract available

  188. HE C, Buongiorno LP, Wang W, Tang JCY, et al
    The Inhibitory Effect of Sulforaphane on Bladder Cancer Cell Depends on GSH Depletion-Induced by Nrf2 Translocation.
    Molecules. 2021;26.
    PubMed    
    Abstract available

  189. CORMIO A, Busetto GM, Musicco C, Sanguedolce F, et al
    Mitofusin-2 Down-Regulation Predicts Progression of Non-Muscle Invasive Bladder Cancer.
    Diagnostics (Basel). 2021;11.
    PubMed    
    Abstract available

  190. PEYROTTES A, Ouzaid I, Califano G, Hermieu JF, et al
    Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer.
    Medicina (Kaunas). 2021;57.
    PubMed    
    Abstract available

  191. DOBRUCH J, Oszczudlowski M
    Bladder Cancer: Current Challenges and Future Directions.
    Medicina (Kaunas). 2021;57.
    PubMed    
    Abstract available

  192. MAGRAY JA, Pandith AA, Qasim I, Khateeb M, et al
    Significant Implications of APOA1 Gene Sequence Variations and Its Protein Expression in Bladder Cancer.
    Biomedicines. 2021;9.
    PubMed    
    Abstract available

  193. LIAO YA, Chiang CJ, Lee WC, Zhuang BZ, et al
    Extranodal Extension Predicts Poor Survival Outcomes among Patients with Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  194. WANG SC, Chang YC, Wu MY, Yu CY, et al
    Intravesical Instillation of Azacitidine Suppresses Tumor Formation through TNF-R1 and TRAIL-R2 Signaling in Genotoxic Carcinogen-Induced Bladder Cancer.
    Cancers (Basel). 2021;13.
    PubMed    
    Abstract available

  195. YANG Y, Chen S, Li P, Jing Y, et al
    PFOI stimulates the motility of T24 bladder cancer cells: Possible involvement and activation of lncRNA malat1.
    Chemosphere. 2021;287.
    PubMed    
    Abstract available

  196. SETTI BOUBAKER N, Gurtner A, Trabelsi N, Manni I, et al
    The diagnostic applicability of A-type Lamin in non-muscle invasive bladder cancer.
    Ann Diagn Pathol. 2021;54:151808.
    PubMed    
    Abstract available

  197. ZHANG P, Zhang Y, Han X, Zhang X, et al
    Effect of individualized psychological intervention on negative emotion and sleep quality of patients after bladder cancer surgery: a randomized controlled trial.
    Transl Androl Urol. 2021;10:3021-3029.
    PubMed    
    Abstract available

  198. SANDERS JA, Frasier C, Matulay JT, Steuerwald NM, et al
    Genomic analysis of response to bacillus Calmette-Guerin (BCG) treatment in high-grade stage 1 bladder cancer patients.
    Transl Androl Urol. 2021;10:2998-3009.
    PubMed    
    Abstract available

  199. YU S, Wang S, Sun X, Wu Y, et al
    ST8SIA1 inhibits the proliferation, migration and invasion of bladder cancer cells by blocking the JAK/STAT signaling pathway.
    Oncol Lett. 2021;22:736.
    PubMed    
    Abstract available

  200. ZHAO L, Sun J, Wang K, Tai S, et al
    Development of a New Recurrence-Free Survival Prediction Nomogram for Patients with Primary Non-Muscle-Invasive Bladder Cancer Based on Preoperative Controlling Nutritional Status Score.
    Cancer Manag Res. 2021;13:6473-6487.
    PubMed    
    Abstract available

  201. BYUN SS, Kim FJ, Khandrika L, Kumar B, et al
    Retraction notice to "Differential effects of valproic acid on growth, proliferation and metastasis in HTB-5 and HTB-9 bladder cancer cell lines" [Canc. Lett. 281/2 (2009) 196-202].
    Cancer Lett. 2021 Aug 21. pii: S0304-3835(21)00399.
    PubMed    
    Abstract available

  202. ZHOU F, Li Z, Dong L, Yang G, et al
    lncRNA ADAMTS9-AS1 promotes bladder cancer cell invasion, migration, and inhibits apoptosis and autophagy through PI3K/AKT/mTOR signaling pathway.
    Int J Biochem Cell Biol. 2021 Aug 21:106069. doi: 10.1016/j.biocel.2021.106069.
    PubMed    
    Abstract available

  203. SAHU D, Huan J, Wang H, Sahoo D, et al
    Bladder Cancer Invasion is Mediated by mTORC2-Driven Regulation of Nitric Oxide and Invadopodia Formation.
    Am J Pathol. 2021 Aug 21. pii: S0002-9440(21)00350.
    PubMed    
    Abstract available

  204. ZHAN X, Guo J, Chen L, Deng W, et al
    Prognostic significance of bladder neck involvement in non-muscle-invasive bladder cancer: A SEER database analysis with 19,919 patients.
    Cancer Med. 2021 Aug 23. doi: 10.1002/cam4.4219.
    PubMed    
    Abstract available

  205. LI HJ, Gong X, Li ZK, Qin W, et al
    Role of Long Non-coding RNAs on Bladder Cancer.
    Front Cell Dev Biol. 2021;9:672679.
    PubMed    
    Abstract available

  206. ZHANG X, Wang J, Lu J, Su L, et al
    Robust Prognostic Subtyping of Muscle-Invasive Bladder Cancer Revealed by Deep Learning-Based Multi-Omics Data Integration.
    Front Oncol. 2021;11:689626.
    PubMed    
    Abstract available

  207. YANG L, Li C, Qin Y, Zhang G, et al
    A Novel Prognostic Model Based on Ferroptosis-Related Gene Signature for Bladder Cancer.
    Front Oncol. 2021;11:686044.
    PubMed    
    Abstract available

  208. YAN X, Du GW, Chen Z, Liu TZ, et al
    CD86 Molecule Might Be a Novel Immune-Related Prognostic Biomarker for Patients With Bladder Cancer by Bioinformatics and Experimental Assays.
    Front Oncol. 2021;11:679851.
    PubMed    
    Abstract available

  209. BISTAZZONI S, Bonetto S, Domenico Bellocchi S
    Solitary Calvarial Metastasis As the First Presentation of Urothelial Bladder Cancer.
    Cureus. 2021;13:e17257.
    PubMed    
    Abstract available

  210. ZHANG Y, Xu Y, Li S
    Bibliometrics Analysis of Diagnostic Test Accuracy Studies of Bladder Cancer.
    Dis Markers. 2021;2021:8870353.
    PubMed    
    Abstract available

  211. QIAN Z, Ding W, Zhou Q, Sun C, et al
    Depression Induced by CUMS Leads to Bladder Cancer Development and Local Tumor Immunosuppression in Mice.
    J Oncol. 2021;2021:5537523.
    PubMed    
    Abstract available

  212. PAN YH, Zhang JX, Chen X, Liu F, et al
    Predictive Value of the TP53/PIK3CA/ATM Mutation Classifier for Patients With Bladder Cancer Responding to Immune Checkpoint Inhibitor Therapy.
    Front Immunol. 2021;12:643282.
    PubMed    
    Abstract available

  213. LIN W, Sun J, Sadahira T, Xu N, et al
    Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer.
    Int J Biol Sci. 2021;17:3255-3267.
    PubMed    
    Abstract available

  214. KOMINA S, Petrusevska G, Janevska V, Jovanovic R, et al
    Effect of bladder cancer variant histology on survival outcome in patients treated with radical cystectomy: A single-centre experience.
    Urol Ann. 2021;13:288-295.
    PubMed    
    Abstract available

  215. SIKIC D, Weyerer V, Geppert CI, Bertz S, et al
    Utility of stromal tumor infiltrating lymphocyte scoring (sTILs) for risk stratification of patients with muscle-invasive urothelial bladder cancer after radical cystectomy.
    Urol Oncol. 2021 Aug 20. pii: S1078-1439(21)00343.
    PubMed    
    Abstract available

  216. LONATI C, Baumeister P, Afferi L, Mari A, et al
    Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guerin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration.
    Eur Urol Focus. 2021 Aug 18. pii: S2405-4569(21)00195.
    PubMed    
    Abstract available

  217. MARIAPPAN P
    The Scottish Bladder Cancer Quality Performance Indicators Influencing Outcomes, Prognosis, and Surveillance (Scot BC Quality OPS) Clinical Project.
    Eur Urol Focus. 2021 Aug 18. pii: S2405-4569(21)00191.
    PubMed    
    Abstract available

  218. LAMM DL, Morales A
    A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment.
    Vaccine. 2021 Aug 17. pii: S0264-410X(21)01046.
    PubMed    
    Abstract available

  219. FURUBAYASHI N, Negishi T, Sakamoto N, Tamura S, et al
    Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    In Vivo. 2021;35:2869-2874.
    PubMed    
    Abstract available

  220. HAMADA A, Sano T, Matsumoto K, Sakatani T, et al
    Modification of Platinum-based Systemic Chemotherapy for Advanced Urothelial Carcinoma in Patients With Suboptimal Renal Function.
    In Vivo. 2021;35:2821-2829.
    PubMed    
    Abstract available

  221. NAGAI T, Naiki T, Isobe T, Sugiyama Y, et al
    Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma.
    In Vivo. 2021;35:2793-2800.
    PubMed    
    Abstract available

  222. VUILLE-LESSARD E, Montani M, Bosch J, Semmo N, et al
    Autoimmune hepatitis triggered by SARS-CoV-2 vaccination.
    J Autoimmun. 2021;123:102710.
    PubMed    
    Abstract available

  223. GMEINER J, Garstka N, Helbich TH, Shariat SF, et al
    Vesical Imaging Reporting and Data System (VI-RADS): Are the individual MRI sequences equivalent in diagnostic performance of high grade NMIBC and MIBC?
    Eur J Radiol. 2021;142:109829.
    PubMed    
    Abstract available

  224. LAWACZECK L, Fischer AK, Norz V, Rausch S, et al
    [BCG-induced (bacillus Calmette-Guerin) abdominal granulomatosis after occult bladder perforation].
    Urologe A. 2021;60:1184-1187.
    PubMed    
    Abstract available

  225. NEUMANN JM, Niehaus K, Neumann N, Knobloch HC, et al
    A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer.
    Lab Invest. 2021;101:1281-1288.
    PubMed    
    Abstract available

  226. ANDREEV-DRAKHLIN AY, Egoryan G, Shah AY, Msaouel P, et al
    The evolving treatment landscape of advanced urothelial carcinoma.
    Curr Opin Oncol. 2021;33:221-230.
    PubMed    
    Abstract available

  227. TREGUNNA R
    Prior UTUC affects bladder tumour progression.
    Nat Rev Urol. 2021;18:190.
    PubMed    


  228. BUTLER DSC, Cafaro C, Putze J, Wan MLY, et al
    A bacterial protease depletes c-MYC and increases survival in mouse models of bladder and colon cancer.
    Nat Biotechnol. 2021;39:754-764.
    PubMed    
    Abstract available

  229. WU YL, Lang L, Ma Q, Wu F, et al
    Perivascular Epithelioid Cell Tumor of Urinary Bladder.
    Am J Clin Pathol. 2021;156:56-71.
    PubMed    
    Abstract available

  230. SIDAWAY P
    Intravesical therapy goes viral.
    Nat Rev Urol. 2021;18:72.
    PubMed    


  231. AL-SHARAKY DR, Abdelwahed M, Asaad N, Foda A, et al
    Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20.
    J Immunoassay Immunochem. 2021;42:236-251.
    PubMed    
    Abstract available

  232. KARAKAIDOS P, Rampias T
    Monitoring of Active Notch Signaling in Mouse Bladder Urothelium.
    Methods Mol Biol. 2021;2346:121-134.
    PubMed    
    Abstract available

  233. DAS JP, Vargas HA, Ghafoor S, Goh AC, et al
    Clinical utility of (18)F-FDG PET/CT in staging and treatment planning of urachal adenocarcinoma.
    J Nucl Med. 2020 Sep 18. pii: jnumed.120.251561. doi: 10.2967/jnumed.120.251561.
    PubMed    
    Abstract available

  234. IMAMURA K, Takada M, Umemoto K, Furukawa S, et al
    Laparoscopic parastomal herniorrhaphy utilizing transversus abdominis release and a modified Sugarbaker technique: A case report.
    Asian J Endosc Surg. 2021;14:106-108.
    PubMed    
    Abstract available

  235. RODGERS SA, Williamson SR
    Xanthogranulomatous Ureteritis Mimicking Ureteral Involvement by Cancer in a Radical Cystectomy Specimen.
    Int J Surg Pathol. 2021;29:334-336.
    PubMed    
    Abstract available

  236. MARTINEZ RODRIGUEZ RH, Amon Sesmero JH
    The search of new biomarkers in the prediction of BCG response in patients with high-risk NMIBC.
    World J Urol. 2021;39:629-630.
    PubMed    


  237. MATSUNAGA W, Hamada K, Tagawa M, Morinaga T, et al
    Cancer Cell-specific Transfection of hCas9 Gene Using Ad5F35 Vector.
    Anticancer Res. 2021;41:3731-3740.
    PubMed    
    Abstract available

  238. MIYATA Y, Tsurusaki T, Hayashida Y, Imasato Y, et al
    Intravesical MMC and MMC+Ara-C for non-muscle invasive bladder cancer: A randomized clinical trial.
    BJU Int. 2021 Aug 12. doi: 10.1111/bju.15571.
    PubMed    
    Abstract available

  239. ELSAWY AA, Abol-Enein H, Laymon M, Ahmed AE, et al
    Predictive Value of Immunological Markers after Bacillus Calmette-Guerin Induction in Bladder Cancer.
    BJU Int. 2021 Aug 27. doi: 10.1111/bju.15582.
    PubMed    
    Abstract available

  240. FURRER MA, Papa N, Luetolf S, Roth B, et al
    A longitudinal study evaluating interim assessment of neoadjuvant chemotherapy for bladder cancer.
    BJU Int. 2021 Aug 21. doi: 10.1111/bju.15579.
    PubMed    
    Abstract available

  241. LAUTZ TB, Chi YY, Li M, Wolden SL, et al
    Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group.
    Cancer. 2021;127:275-283.
    PubMed    
    Abstract available

  242. KARTOLO A, Kassouf W, Vera-Badillo FE
    Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?
    Eur Urol. 2021 Aug 5. pii: S0302-2838(21)01922.
    PubMed    
    Abstract available

  243. LI R, Jain RK, Sexton WJ
    Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6.
    Eur Urol. 2021 Aug 4. pii: S0302-2838(21)01925.
    PubMed    


  244. KESAVAN A, Esuvaranathan K
    Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicentre, Phase 2 Study.
    Eur Urol. 2021 Aug 4. pii: S0302-2838(21)01923.
    PubMed    


  245. SHIN T, Mimata H
    "Early-pull-out" technique for intracorporeal ileal conduit urinary diversion after robot-assisted radical cystectomy.
    Int J Urol. 2021;28:778-779.
    PubMed    


  246. SHINDO T, Hashimoto K, Tanaka T, Taguchi K, et al
    Therapeutic options to reduce intravesical recurrence in newly diagnosed Ta high-grade bladder cancer according to risk stratification: A multicenter retrospective study.
    Int J Urol. 2021 Aug 3. doi: 10.1111/iju.14657.
    PubMed    
    Abstract available

  247. SETOGUCHI K, Saito K
    Editorial Comment from Dr Setoguchi and Dr Saito to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:821-822.
    PubMed    


  248. SHIGA M, Nagumo Y, Chihara I, Nitta S, et al
    Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:814-819.
    PubMed    
    Abstract available

  249. HATAKEYAMA S, Ohyama C
    Editorial Comment from Dr Hatakeyama and Dr Ohyama to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:820.
    PubMed    


  250. SAZUKA T
    Editorial Comment from Dr Sazuka to Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan.
    Int J Urol. 2021;28:820-821.
    PubMed    


  251. ROSE TL, Harrison MR, Deal AM, Ramalingam S, et al
    Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
    J Clin Oncol. 2021 Aug 24:JCO2101003. doi: 10.1200/JCO.21.01003.
    PubMed    
    Abstract available

  252. MERSEBURGER AS, Castellano D, Powles T, Loriot Y, et al
    Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
    J Urol. 2021;206:240-251.
    PubMed    
    Abstract available

  253. PATEL SR, Lerner SP
    Novel Thermo-Sensitive Hydrogel Therapy for Low-Grade Upper Tract Urothelial Carcinoma.
    J Urol. 2021;206:191-193.
    PubMed    


  254. D'ANDREA D, Black PC, Zargar H, Dinney CP, et al
    Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle-Invasive Bladder Cancer.
    J Urol. 2021 Aug 27:101097JU0000000000002190. doi: 10.1097/JU.0000000000002190.
    PubMed    
    Abstract available

  255. PATEL HD, Patel SH, Blanco-Martinez E, Kuzbel J, et al
    Four versus Three Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathologic Response and Survival.
    J Urol. 2021 Aug 27:101097JU0000000000002189. doi: 10.1097/JU.0000000000002189.
    PubMed    
    Abstract available

  256. CHEVLI KK, Shore ND, Trainer A, Smith AB, et al
    Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, A Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
    J Urol. 2021 Aug 26:101097JU0000000000002186. doi: 10.1097/JU.0000000000002186.
    PubMed    
    Abstract available

  257. TOHI Y, Miyauchi Y, Yamasaki M, Fujiwara K, et al
    Incidental Bladder Cancer Found on Cystoscopy during Prostate Biopsy: Prevalence, Pathological Findings, and Oncological Outcome.
    Urol Int. 2021 Aug 5:1-7. doi: 10.1159/000517895.
    PubMed    
    Abstract available

  258. RAVENTOS BUSQUETS CX, Semidey ME, Lozano Palacio F, Carrion Puig A, et al
    Is Tumor Budding a New Predictor for Early Cystectomy in pT1 High-Grade Bladder Cancer?
    Urol Int. 2021 Aug 5:1-9. doi: 10.1159/000517543.
    PubMed    
    Abstract available

  259. RUCKHER J, Lobitz J, Follmann M, Derenz S, et al
    Guideline-Based Quality Indicators for Kidney and Bladder Cancer in Germany: Development and Implementation.
    Urol Int. 2021 Aug 12:1-8. doi: 10.1159/000517893.
    PubMed    
    Abstract available

  260. SUER E, Karaburun MC, Babayigit M, Akpinar C, et al
    Does switching Bacillus Calmette-Guerin strains during maintenance therapy affect the outcome in non-muscle invasive bladder cancer?
    Urology. 2021 Aug 21. pii: S0090-4295(21)00781.
    PubMed    
    Abstract available

  261. LI J, Cao J, Li P, Yao Z, et al
    Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    BMC Cancer. 2021;21:858.
    PubMed    
    Abstract available

  262. WANG X, Guo J, Wang L, Wang M, et al
    Modified completely intrafascial radical cysprostatectomy for bladder cancer: a single-center, blinded, controlled study.
    BMC Cancer. 2021;21:887.
    PubMed    
    Abstract available

  263. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    PubMed    
    Abstract available

  264. RIPOLL J, Ramos M, Montano J, Pons J, et al
    Correction to: Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival.
    BMC Cancer. 2021;21:956.
    PubMed    


  265. LIANG Y, Ye F, Xu C, Zou L, et al
    A novel survival model based on a Ferroptosis-related gene signature for predicting overall survival in bladder cancer.
    BMC Cancer. 2021;21:943.
    PubMed    
    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;